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New phenomena in the clinical and morphological aspects 
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Tatyana V. Pavlova*, Ilya P. Bashuk, Natalia B. Pilkevich, Liubov A. Pavlova
INTRODUCTION
Osteoporosis is one of the important problems of 
health care, as its frequency constantly grows.[1] The 
social significance of osteoporosis is determined by 
the high prevalence of this pathology and mortality 
from its outcomes - fractures of femur and spine, loss 
of ability of work and self-service, bigger economic 
costs on prophylactics, treatment, and service. In 
city population, 24% of women and 13% of men at 
the age of 50 and over have already had fractures 
according to the data of federal center of prophylactics 
of osteoporosis.[2,3] Nowadays, more than 200 million 
people are suffered from osteoporosis. According 
to estimation in the Russian Federation, 14 million 
people (10% of country’s population) are suffered 
from osteoporosis, and another 20 million people 
have osteopenia. Thus, 24% of citizens of Russian 
Federation (34 million people) enter into a group 
of the potential risk of osteoporotic fractures.[4] It is 
known that one osteoporotic fracture takes place in 
every third woman in the age over 50.[4,5] Annually, 
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the frequency of femur fractures is 105.9 per 100,000 
population, and the frequency of fractures of the distal 
part of the forearm is 462.2/100,000 population.[5] 
According to statistic data, 10% loss of bone mineral 
density (BMD) in bodies of vertebra leads to increasing 
of the risk of their fractures in 2 times, and the similar 
decreasing of BMD in femur leads to increasing of 
distal femur fracture in 2.5 times.[6]
The Aim of Work
The aim of this study is to compare the biochemical 
indexes of phosphorus-calcium (Ca) metabolism 
in patients with metabolic syndrome of 1–5 stages, 
associated with osteoporosis with morphological 
picture of bone tissue.
MATERIALS AND METHODS
A total of 248 patients (99 men and 149 women) in 
the age from 60 to 69 (mean age was 64 ± 3.5) were 
examined during the study. Metabolic syndrome 
divided into stages depending on the degree of 
obesity: 1 stage - metabolic syndrome with pre-obesity 
(increased normal body weight); 2 stage - metabolic 
syndrome with the obesity of 1° (51 patients); 3 
stage - metabolic syndrome with the obesity of 2° 
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(46 patients), 4 stage - metabolic syndrome with the 
obesity of 3° (38 patients), and 5 stage - metabolic 
syndrome with the obesity of 4° (56 patients).
Next, indexes were estimated in patients: Height, 
weight, arterial pressure, cholesterol and glucose 
statuses, presence of heart insufficiency and its 
expression according to NYHA classification, common 
laboratory indexes, serum electrolytes, including 
ionized and albumin-corrected Ca (which can be 
counted by formula Ca corr.=Са total+([40–albumin 
in g/l] × 0.02]), product of Ca×phosphate (P), total 
alkaline phosphatase (AF), lipidogram, C-reactive 
protein, fibrinogen, and parathyroid hormone (PTH). 
Daily proteinuria, daily excretion, and excreted 
fractions of urea, creatinine, and electrolytes were 
determined. 25(OH)D и 1.25(OH)
2
D of blood serum, 
osteocalcin, C-telopeptide of collagen type 1, and 
genetic polymorphism of Vitamin D receptor were 
researched by with help of a set of company “IDS.”
Dual-energy X-ray absorptiometry of three parts of the 
skeleton (lumbar vertebrae L1-L4, proximal part of 
femur, and distal part of forearm) for the determination 
of BMD was performed on device Hologic QDR 
4500С. BMD was estimated by T-criteria (number 
of RMS deviations from peak bone mass of healthy 
people) and Z-criteria (RMS deviation from bone 
mass of healthy people of same age, sex, and race).
The degree of decreasing of bone mass on radiographs 
of the wrists was determined by the thickness of two 
cortical layers of second metacarpal bone. It was 
calculated by formula (bone diameter in the middle 
of diaphysis minus diameter of medullary canal) and 
by the Barnett–Noordin index (the ratio of diaphysis 
diameter to thickness of cortical layers).[7]
The specimens, taken after surgery for light 
microscopy, were poured into paraffin blocks. The 
specimens were viewed and photographed in light 
microscope TOPIC-T (“CETI Medline Scientific Ltd,” 
Great Britain). The samples were viewed in raster 
microscope “FE Quanta 200 3D” and “FE1 Quanta 
600 FEG” (Netherlands) with the function of non-
contact determination of the percentage of macro- and 
microelements. Macro- and microelemental analysis 
was performed with use of a detector for the registration 
of specters of characteristic X-ray radiation (company 
“EPAX”). Detectors were integrated with raster 
electron microscope “Quanta 600 FEG.” The study 
was based on the appearance of continuous fluorescent 
radiation at bombarding of researched samples by a 
beam of primary X-ray.
The estimation of microvolumes of substance is the 
method of X-ray spectral analysis. Microfocus X-ray 
tube, combined with optical microscope, is the base of 
microanalyzer. Special electron optical system makes 
thin electron probe, which bombarding small area 
(1–2 μm) of examined section located on the anode. 
Microspectral analysis is conducted by spectrograph 
with curved crystal for the determination of several 
elements in defined point of section and for exploration 
of the distribution of one of them across chosen 
direction. The exploration of the defined surface of 
analyzed specimen by electron probe displays on 
the screen the distribution of chemical elements on 
surface of section. Absolute sensitivity of the method 
is 10–13–10–15 g. The fault at elemental analysis is 
0.2–0.25% (by concentration). The exploration of 
the content of macroelements (Ca, oxygen, sodium, 
potassium, magnesium, phosphorus, sulfur, nitrogen, 
and chlorine) and microelements (fluorine and silicon) 
was conducted.[8,9]
The statistic processing of material was performed 
with use of standard programs of applied statistical 
analysis (Statistica 6.0). Methods of descriptive 
statistics (mean arithmetic, median, and mean square 
deviation), Student’s t-test, and the Wilcoxon Mann–
Whitney U-test, the Pearson’s c2 criteria, single-
factor variance analysis (ANOVA), linear correlation 
analysis (Pearson’s r-criteria and Spearman’s Rs-
criteria), and multifactorial methods (multiple linear 
regression analysis and discriminant analysis) were 
used. The numeric data are given as mean values with 
a standard deviation (M±SD), mean values are shown 
on the bar graphs, and the vertical lines reflect a 95% 
confidence interval. Critical level of reliability of the 
null statistical hypothesis was 0.05.[10]
RESULTS AND DISCUSSION
Beginning from 2nd stage of metabolic syndrome, the 
level of PTH in serum grew as metabolic syndrome 
progressed (in comparison with 1st stage P = 0.013). 
Such early increasing of the level of PTH was 
detected for the 1st time. The tendency to decrease 
the physiologically active ionized Ca was detected as 
metabolic syndrome progressed, and besides its level 
on 5th stage was lower than on 4th stage (P = 0.032). 
The significant decreasing of daily excretion of Ca was 
observed at increasing of chronic heart insufficiency 
(F=17.8; p
ANOVA 
< 0.001).
The excreted fraction of Ca had a tendency to increase 
on 4th stage in comparison with 3rd stage (P = 0.051), 
and it increased rapidly on 5th stage (in comparison 
with 4th stage). The phosphorus of serum decreased on 
2nd stage in comparison with 1st stage (P < 0.001), it 
began to increase from 4th stage. The daily excretion 
of P with urine decreased from 4th stage of metabolic 
syndrome (F=9.6; p
ANOVA
<0.001). The excreted 
fraction of P had increased quickly since 2 stage of 
metabolic syndrome (in comparison with 1 stage 
P = 0.001). The decrease of the level of 1.25(OH)
2
D 
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in serum was observed due to decrease of its synthesis 
in renal tubules in consequence of nephrosclerosis and 
hyperphosphatemia (Rs = −0.26; P = 0.016).
The values of 25(OH)D were stable on all stages of 
metabolic syndrome (F=0.3; p
ANOVA 
= 0.9). According 
to the results of multiple regression analysis, the level 
of PTH was higher in patients who had high functional 
class of chronic heart insufficiency (t = 6.70; 
P < 0.001), low level of Ca (t = 1.97; P = 0.052), and 
more higher level of P in serum (t = 2.41; P < 0.016). 
Daily excretion of Ca (t = 4.09; P < 0.001) and Р 
(t = 1.78; P = 0.076) was higher in patients with higher 
level of 1.25(OH)
2
D in blood (R2 = 0.24; F = 12.9; P < 
0.001). This dependence can be explained by the fact 
that 1.25(OH)
2
D stimulates absorption of Ca and P in 
intestine and resorption of Ca from bones, what finally 
determines the amount of excretion of these substances 
by the kidneys. The concentration of 1.25(OH)
2
D 
directly depended (R2 = 0.19; F = 10.0; P < 0.001) 
from functional class of chronic cardiac insufficiency 
(t = 3.42; P = 0.001) and values of 25(OH)D in 
serum (t = 1.89; P = 0.068). Thus, the insufficiency 
of 25(OH)D as a substrate of active form of Vitamin 
D - 1.25(OH)
2
D - negatively influences on level of last 
one in some degree. Feedback of level 1.25(OH)
2
D 
with daily proteinuria (Rs = −0.27; P = 0.012) can 
be considered as antiproteinuric, nephroprotective 
effect of D-hormone. The value of Ca in blood was 
determined (R2 = 0.09; F = 5.35; P = 0.025) only by 
the level of 1.25(OH)
2
D in serum (t = 2.31; P = 0.024). 
Daily excretion of Р (R2 = 0.08; F = 4.4; P = 0.009) 
also depended only from the level of D-hormone 
in blood (t = 2.76; P = 0.024). As chronic cardiac 
insufficiency progressed, excreted fractions of Ca and 
P were increased (Rs = −0.22; P < 0.001 и Rs = −0.71; 
P < 0.001), and besides the last one directly correlated 
with level of PTH in serum (Rs = 0.51; P < 0.001).
Consequently, the decreasing of daily excretion of 
Ca and P, probably, connected with decreasing of 
production of 1.25(OH)
2
D during progression of 
metabolic syndrome. Significant growth of excreted 
fraction P is conditioned by increasing of PTH in 
serum.
In patients, examined in period April–June, the 
level of 25(OH)D was significantly lower than 
in September–December (55.7 ± 46.4 and 91.6 ± 
47.7 pmol/L, P = 0.002). There were no season 
differences of 1.25(OH)
2
D. The deficit of 25(OH)D 
(<37.5 mmol/l) was detected in 25.9%, the deficit of 
1.25(OH)
2
D (<53.2 pmol/L) was in 61.5% of patients, 
and the insufficiency of 25(OH)D (below the optimal 
level - 75 pmol/l) was in 77.9% of patients.
Mean value of BMD of three parts of the skeleton 
was determined by dual-energy X-ray absorptiometry 
in 192 patients with the metabolic syndrome 
of 1–4 stages and in 56 patients with metabolic 
syndrome of the 5th stage. According to T-criteria, 
the share of patients with normal BMD was 61.3%, 
patients with osteopenia - 26.3%, and patients with 
osteoporosis - 12.7%. In group of patients with 
chronic heart insufficiency of 4 functional class – 
35.9%, 31.3% and 32.8% respectively. In patients with 
metabolic syndrome of 5th stage, BMD of the forearm 
and proximal part of the femur were significantly 
lower in comparison with another group (P < 0.001), 
and the tendency to more lower values of BMD of 
lumbar vertebrae was also observed (P = 0.08). The 
values of BMD of the forearm were the lowest and 
BMD of vertebrae were maximal (in comparison with 
forearm t = 1.98; P = 0.047) in this group. In group of 
patients with metabolic syndrome of 1–4 stages, there 
was a tendency to lower values of BMD of the forearm 
in comparison with proximal part of femur (P = 0.08).
BMI directly influenced on BMD of vertebrae in 
patients with metabolic syndrome of 5th stage (Rs = 0.41; 
P < 0.001). The connection with gene polymorphism 
of the receptor of Vitamin D TAQI was revealed: BMD 
was higher in patients with genotype IT in comparison 
with genotypes Tt and TT. Gene polymorphisms 
such as BSMI and APAI did not influence on BMD. 
According to the data of correlative analysis, BMD of 
the proximal part of femur was lower in women (in 
comparison with men) (Rs = −0.26; P = 0.047), in patient 
with lower BMI (Rs = 0.54; P < 0.001), in patients 
with ischemia of myocardium on electrocardiography 
monitoring (Rs = −0.24; P = 0.047), and in cases of 
expressed heart insufficiency (Rs = −0.32; P = 0.015). 
It is necessary to note that BMD of the proximal part 
of the femur was lower in patients with mitral stenosis 
in comparison with patients without this pathology 
(t = 3.18; P = 0.004).
Values of BMD of forearm correlated directly with 
body mass of patient (Rs = 0.42; P < 0.001). The 
feedback was revealed with degree of expression 
of chronic cardiac insufficiency (Rs = −0.46; 
P < 0.001) and with indexes, which reflected 
speed of metabolism in bones and expression of 
hyperparathyroidism (levels of PTH (Rs = −0.36, 
P = 0.003), AF (Rs = −0.55, P < 0.001), osteocalcin 
(Rs = −0.39; P = 0.018), and C-telopeptides of type I 
Figure 1: (a and b) Fragments of bone tissue at osteoporosis
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collagen (Rs = −0.53, P < 0.001). Thus, at the chronic 
cardiac insufficiency of 4th functional class (as a result 
of metabolic syndrome), BMD of forearm decreased 
more significantly in comparison with the proximal 
part of femur, while densitometric parameters of 
vertebrae did not change. Perhaps, the loss of bone 
mass in the periphery of the skeleton was conditioned 
by insufficient correction of hyperparathyroidism.
The direct link of BMD of forearm with BMI 
(Rs = 0.43; P < 0.001), functional class of chronic 
cardiac insufficiency (Rs = 0.22; P = 0.018), and level 
of hemoglobin (Rs = 0.21; P = 0.027) were detected 
in patients with metabolic syndrome of 1–4 stages 
at correlative analysis. The feedback of BMD of the 
forearm with the product of Са×Р of blood on the 
level of tendency was revealed (Rs = −0.18; P = 0.08). 
The revealed decreasing of BMD at the progression of 
chronic cardiac insufficiency (F = 6.2; p
ANOVA 
= 0.003) 
can be explained by the progression of secondary 
hyperparathyroidism and decreasing of 1.25(OH)
2
D 
concentration.
In patients with metabolic syndrome, the bone 
density decreases as metabolic syndrome progresses. 
Osteopenic alterations are more expressed in bones of 
the forearm and associated with the development of 
hyperparathyroidism. The content of potassium and 
phosphorus increased on 1st and 8th weeks in matrix 
bone (6.58 ± 1.34%; 7.05 ± 1.84%) (2.38 ± 0.04%; 
3.53 ± 0.45%) and newly formed bone (14.93 ± 2.94%; 
10.04 ± 2.74%; 3.77 ± 0.01%; 5.71 ± 0.30%); the 
content of potassium and phosphorus in comparison 
with undamaged bone (5.46 ± 1.02%; 2.01 ± 0.02%).
The structure of bone tissue is violated. Cavities with 
sides of necrosis and fragments of destructed tissue 
were observed [Figure 1a and b].
The content of hydrophobic elements in mineral 
component of humerus, Ca and P, increased from 
13.54 ± 0.37% to 21.07 ± 0.53% and from 14.35 ± 
0.23% to 21.13 ± 0.15%, respectively. Herewith, the 
ratio Ca/phosphorus increased from 0.94 ± 0.03% to 
1.06 ± 0.04% in period from 7 to 90 days.
Thus, phosphorus-Ca imbalance in patients with 
metabolic syndrome was determined on the 2nd stage 
when chronic cardiac insufficiency of 1 functional 
class took place as a result of metabolic syndrome. 
It is manifested by decreasing 1.25(OH)
2
-Vitamin D 
and increasing of PTH in blood serum, what is 
associated with the beginning of osteoporosis. The 
level of phosphate decreased transiently due to 
increasing of PTH in blood, after that it progressively 
grew, what allowed to note leading role of violation 
of phosphate metabolism in the development of 
hyperparathyroidism. In patients with metabolic 
syndrome of 1–4 stages, BMD decreases as 
metabolic syndrome progresses. Osteopenia/
osteoporosis was more expressed in bones of the 
forearm and connected with hyperparathyroidism 
in patients with metabolic syndrome of the 5th stage. 
The data of biochemical studies are comparable 
with information, taken with the help of electron 
microscopy.
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